Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. (CPI)

11 september 2026 uppdaterad av: Centre Antoine Lacassagne
This is a single-center pharmacokinetic study evaluating the impact of residual pembrolizumab levels on the efficacy of salvage chemotherapy following immunotherapy in patients with non-small cell lung cancer (NSCLC) or recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) not amenable to curative local treatment.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

110

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

- Patients over 18 years of age

- Patients diagnosed with :

  1. Non-small cell lung cancer (NSCLC), including adenocarcinoma and squamous cell carcinoma.
  2. Head and neck squamous cell carcinoma, p16-negative for oropharyngeal tumors.

    • Recurrent and/or metastatic tumor not amenable to curative locoregional treatment.
    • Disease progression under Pembrolizumab immunotherapy, administered at the standard dose of 200 mg every 3 weeks, as first-line treatment for metastatic disease, regardless of the number of cycles received, either as monotherapy or in combination with chemotherapy, as defined below:

      • For pulmonary adenocarcinomas: i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin or Cisplatin) and Pemetrexed

    ii. Maintenance therapy with Pembrolizumab, with or without Pemetrexed.

    • For pulmonary squamous cell carcinomas: i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin) and Paclitaxel

    +/- ii. Maintenance therapy with Pembrolizumab alone.

    • For head and neck squamous cell carcinomas : i. First-line treatment with Pembrolizumab in combination with a platinum agent (Carboplatin or Cisplatin) ± 5-Fluorouracil (5-FU) or Paclitaxel

    +/- ii. Maintenance therapy with Pembrolizumab alone.

    • Eligibility for salvage chemotherapy within standard care:

      • For pulmonary adenocarcinomas: weekly Paclitaxel, with or without Bevacizumab.

      • For pulmonary squamous cell carcinomas: Gemcitabine monotherapy.
      • For head and neck squamous cell carcinomas: weekly Paclitaxel and/or Cetuximab. Standard salvage chemotherapy may be initiated between Day 18 and Day 35 following the last Pembrolizumab injection, at standard doses.
    • Measurable disease according to RECIST 1.1 criteria.
    • Performance status (PS) 0 to 2.
    • Baseline laboratory results meeting the usual criteria permitting initiation of salvage chemotherapy.
    • Patients who has voluntarily agreed to participate in the study (including additional blood sampling) and has signed the informed consent form.
    • For the subpopulation with accessible tissue biopsy:

      • Patient agrees to undergo biopsy,
      • INR < 1.5, Platelets > 50000/μL.
    • Patients covered by a social security health insurance scheme.

    Exclusion Criteria:

    • History of cancer, except for cancers in complete remission for more than 3 years, fully resected cutaneous basal cell carcinomas, or treated carcinoma in situ or cervical intraepithelial neoplasia (in situ cervical epithelioma),
    • Patients participating in another clinical trial for which an exclusion period is specified,
    • Minor patients,
    • For the subpopulation with accessible tissue biopsy, patients receiving:

      • Clopidogrel (hydrogen sulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) without the possibility of discontinuation for 5 days,

      • Low-molecular-weight heparin (LMWH) without the possibility of dose suspension prior to the procedure,

      • Or Fondaparinux without the possibility of discontinuation,

      • Or Abciximab without the possibility of discontinuation for 24 hours and aPTT < 50s and ACT < 150s,

      • Or Eptifibatide or Tirofiban hydrochloride monohydrate or Argatroban without the possibility of discontinuation 4 hours before the procedure,

      • Or Bivalirudin without the possibility of discontinuation 2-3 hours before the procedure if CrCL > 50 mL/min, or 3-5 hours if CrCL < 50 mL/min,
      • Or Dabigatran etexilate without the possibility of discontinuation 2-3 days before the procedure if CrCL > 50 mL/min, or 3-5 days if CrCL < 50 mL/min.
    • Vulnerable persons as defined in Articles L1121-5 to L1121-8 :

      • Pregnant women, women in labour, and breastfeeding mothers,

      • Persons deprived of liberty by judicial or administrative decision, and persons hospitalized without consent under Articles L3212-1 and L3213-1 who do not fall under the provisions of Article L1121-8,
      • Persons admitted to a health or social care institution for purposes other than research,
      • Adults under legal protection measures or unable to express their consent.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Residual Pembrolizumab Exposure Assessment
Patients will be followed according to standard clinical care. Biological samples collected include: (1) pharmacokinetic and extracellular vesicle analyses: 10 mL blood samples in EDTA tubes at 21±3, 35±3, 49±3, and 63±3 days after the last pembrolizumab administration (P1-P4); (2) pharmacogenetic analysis: one baseline 5 mL EDTA blood sample; (3) cytokine and immune cell analyses: at P1 and P4, collection of 2×4 mL lithium heparin tubes, 1×10 mL EDTA tube, and 1×5 mL dry tube.

Depending on feasibility of the procedure, and at the discretion of the investigator, two biopsies will be performed in 20 consenting patients:

  • Biopsy B1: between the last administration of pembrolizumab (Day 0) and before initiation of standard salvage chemotherapy,
  • Biopsy B2: after initiation of salvage chemotherapy, at Day 63 ± 7 days after the last administration of pembrolizumab. If chemotherapy is discontinued prematurely, Biopsy B2 may only be performed if the patient has received at least 3 weeks of chemotherapy exposure.

Due to logistical constraints, these biopsies will be proposed to patients followed at CAL. They will be performed primarily in the interventional radiology department of CAL.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Objective response rate (ORR) at 3 months after initiation of salvage chemotherapy (RECIST v1.1)
Tidsram: 3 months after initiation of salvage chemotherapy

Objective response rate (ORR) includes the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria.

Tumor response will be assessed using routine imaging performed during standard clinical follow-up care.

ORR will be analyzed in relation to residual pembrolizumab (anti-PD-1) serum concentration measured 21 days after the last administration of pembrolizumab (P1), immediately prior to initiation of salvage chemotherapy.

3 months after initiation of salvage chemotherapy

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 oktober 2026

Primärt slutförande (Beräknad)

1 maj 2029

Avslutad studie (Beräknad)

1 maj 2029

Studieregistreringsdatum

Först inskickad

29 maj 2026

Först inskickad som uppfyllde QC-kriterierna

4 juni 2026

Första postat (Faktisk)

8 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 september 2026

Senast verifierad

1 september 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera